MiMedx Group Inc (MDXG)vsVertex Pharmaceuticals Inc (VRTX)
MDXG
MiMedx Group Inc
$3.74
-1.06%
HEALTHCARE · Cap: $533.23M
VRTX
Vertex Pharmaceuticals Inc
$446.83
+1.24%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 3038% more annual revenue ($12.22B vs $389.42M). VRTX leads profitability with a 35.5% profit margin vs 7.9%. VRTX appears more attractively valued with a PEG of 1.65. VRTX earns a higher WallStSmart Score of 68/100 (B-).
MDXG
Buy52
out of 100
Grade: C-
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.8%
Fair Value
$46.31
Current Price
$3.74
$42.57 discount
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 99.5% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Smaller company, higher risk/reward
7.9% margin — thin
Weak financial health signals
Expensive relative to growth rate
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MDXG
The strongest argument for MDXG centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : MDXG
The primary concerns for MDXG are Market Cap, Profit Margin, Piotroski F-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
MDXG profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
MDXG carries more volatility with a beta of 1.46 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 52/100), backed by strong 35.5% margins. MDXG offers better value entry with a 88.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MiMedx Group Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?